News   /   Reports

COVIRAN vaccine starts efficacy tests after proving safe

© Press TV

Yusef Jalali
Press TV, Tehran

Among the eight viable vaccine candidates in Iran, COVIRAN is inching closer to the market.

Produced by the Headquarters for executing Imam Khomeini's Order, COVIRAN kickstarted the second and third human trial phases at the same time on Monday.

Volunteers say they feel proud to be part of this great endeavor for humanity.

The vaccine wrapped up its first phase a month ago.

Phase 1 sought to test whether or not the vaccine is safe to be injected to everyone.

Now the second phase will assess the efficacy of the vaccine against the virus.

As the virus keeps mutating to more lethal forms, COVIRAN experts are certain that the Iranian vaccine is effective at least against the British version of the virus.

Iran is working on seven other homegrown vaccines, including COV-PARS, which is now undergoing the first phase of the human trials.

This as the country has already started mass vaccination, mainly using Russia's Sputnik V.

The question of how much immunity COVIRAN will make will only be answered once the second stage is over. Meanwhile, developers say they have already kicked off mass production of the vaccine to catch up with the country's plan to base its national vaccination program on a domestic vaccine.

Press TV’s website can also be accessed at the following alternate addresses:

Press TV News Roku